In Brief: Boston Life Sciences
This article was originally published in The Gray Sheet
Executive Summary
Boston Life Sciences: Initial studies of the firm's Altropane imaging agent for rapid single photon emission computerized tomography (SPECT) scan diagnosis of Parkinson's disease show the agent "allows for accurate diagnosis of Parkinson's disease in less than two hours after injection," the firm states in a June 5 release. Studies of 15 subjects, including seven healthy patients and eight Parkinson's patients, were presented at the annual Society of Nuclear Medicine meeting in San Antonio, Texas during the week of June 2. The studies "demonstrated that Altropane accumulated rapidly and selectively in the dopamine transporters" of healthy patient brains and that accumulation "was markedly reduced" in Parkinson's patients, the firm says...